Press Releases

Date Title
Toggle Summary FDA Grants TransTech Pharma Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer's Disease
High Point, North Carolina (March 18, 2013) TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease.
View HTML
Toggle Summary TTP054, a Novel, Orally Active Drug for Glucose Control, Progresses Towards Completion of a Phase 2 Proof-of-Concept Clinical Trial in Type 2 Diabetics
High Point, North Carolina (November 1, 2012) TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013.
View HTML
Toggle Summary Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients
High Point, North Carolina (October 29, 2012) A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to
View HTML